Company intelligence / Profile preview

Jiangsu Vanguard Pharmaceutical Co., Ltd.

Ownership: Private
Development stage: Commercial

Overview

The company has multiple drugs in clinical development, with GD-11 for Acute Ischemic Stroke in Phase 3, and Conivaptan Hydrochloride and Alvimopan Dihydrate in Phase 2 trials

Therapeutic areas: GastroenterologyOncologyNephrologyNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

GD-11

Beyond the preview

Go deeper on Jiangsu Vanguard Pharmaceutical Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangsu Vanguard Pharmaceutical Co., Ltd..

Explore the full profile